We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+102%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$346M
AUM Growth
+$140M
Cap. Flow
+$48.5M
Cap. Flow %
14.01%
Top 10 Hldgs %
48.64%
Holding
51
New
19
Increased
12
Reduced
13
Closed
5

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$15.9M
2
KURA icon
Kura Oncology
KURA
+$9.73M
3
LRMR icon
Larimar Therapeutics
LRMR
+$8.24M
4
IMVT icon
Immunovant
IMVT
+$7.5M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$7.32M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$16.8M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.2M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$8.12M
4
ARVN icon
Arvinas
ARVN
+$6.67M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.84M

Sector Composition

Rank Sector Weight
1 Healthcare 91.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
1
DELISTED
Adverum Biotechnologies
ADVM
$36.5M 10.54%
174,650
+4,200
+2% +$744K
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$19.3M 5.58%
+545,000
New +$15.9M
BTAI icon
3
BioXcel Therapeutics
BTAI
$26.2M
$18.1M 5.22%
21,281
+1,593
+8% +$1.04M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$1.93B
$16.2M 4.68%
590,000
+190,500
+48% +$6.26M
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$14.8M 4.28%
25,300
-7,800
-24% -$2.66M
KURA icon
6
Kura Oncology
KURA
$816M
$14.2M 4.11%
872,500
+674,500
+341% +$9.73M
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$14.2M 4.09%
1,752,218
-921,500
-34% -$8.12M
CLDX icon
8
Celldex Therapeutics
CLDX
$2.96B
$13M 3.76%
+1,000,000
New +$4.43M
ADAP
9
DELISTED
Adaptimmune Therapeutics
ADAP
$11.7M 3.37%
+1,165,000
New +$7.32M
RLMD icon
10
Relmada Therapeutics
RLMD
$556M
$10.5M 3.03%
234,500
+143,550
+158% +$6.07M
LRMR icon
11
Larimar Therapeutics
LRMR
$413M
$10.3M 2.97%
823,169
+707,669
+613% +$8.24M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.24B
$9.05M 2.62%
1,900,000
+1,650,000
+660% +$6.59M
GYRE icon
13
Gyre Therapeutics
GYRE
$681M
$8.79M 2.54%
199,720
+15,107
+8% +$709K
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.69M 2.51%
78,000
+22,000
+39% +$1.91M
IMVT icon
15
Immunovant
IMVT
$7.91B
$8.52M 2.46%
+350,000
New +$7.5M
ASND icon
16
Ascendis Pharma A/S
ASND
$16B
$8.21M 2.37%
55,500
-7,700
-12% -$1.06M
BLU
17
DELISTED
BELLUS Health Inc.
BLU
$7.87M 2.27%
765,000
-305,000
-29% -$3.09M
AXSM icon
18
Axsome Therapeutics
AXSM
$10.9B
$7.41M 2.14%
90,000
-218,500
-71% -$16.8M
MRUS
19
DELISTED
Merus
MRUS
$7.4M 2.14%
+460,000
New +$6.66M
RNAC icon
20
Cartesian Therapeutics
RNAC
$231M
$6.71M 1.94%
78,807
– –
APLT
21
DELISTED
Applied Therapeutics
APLT
$6.58M 1.9%
182,000
+80,000
+78% +$3.35M
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.55M 1.89%
1,280,000
-1,080,000
-46% -$4.84M
XENE icon
23
Xenon Pharmaceuticals
XENE
$6.02B
$6.49M 1.87%
517,500
-111,000
-18% -$1.41M
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
$6.21M 1.79%
190,000
-19,500
-9% -$626K
LSACU
25
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$6.16M 1.78%
560,000
– –
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Acuta Capital Partners held 51 positions worth $346M, up 68% from $206M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Acuta Capital Partners deployed $48.5M of net new capital in Q2 2020, opening 19 new positions and adding to 12 existing holdings. Its largest new stake was Immunomedics Inc: 545,000 shares worth $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $16.8M trimmed.

  • Acuta Capital Partners's largest Q2 2020 buy was Immunomedics Inc: 545,000 shares worth $19.3M.
  • Acuta Capital Partners added most to Kura Oncology in Q2 2020, an estimated $9.73M increase.
  • Acuta Capital Partners's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $16.8M.
  • Acuta Capital Partners fully exited Aurinia Pharmaceuticals in Q2 2020, selling an estimated $11.2M.
  • Acuta Capital Partners's ten largest holdings make up 49% of its $346M portfolio in Q2 2020.
  • Acuta Capital Partners opened 19 new positions and closed 5 in Q2 2020.
  • Acuta Capital Partners's portfolio value rose 68% quarter-over-quarter to $346M.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.